Ionis Pharmaceuticals, Inc. (IONS) FY2026 YTD Q2 P&L / Income Statement

Ionis Pharmaceuticals, Inc. (IONS) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

514,042,000 US dollars

Cost of sales

5,721,000 US dollars

Gross profit (calculated)

508,321,000 US dollars

Operating expenses (calculated)

728,035,000 US dollars

Income (loss) from operations

negative 219,714,000 US dollars

Other income (expense), net (calculated)

14,022,000 US dollars

Income (loss) before income tax benefit (expense)

negative 205,692,000 US dollars

Income tax benefit (expense)

1,482,000 US dollars

Net income (loss)

negative 207,174,000 US dollars

Biogen

195,552,000 US dollars

Glaxo Smith Kline Collaboration Member

30,000,000 US dollars

Ono

23,805,000 US dollars

Otsuka

29,318,000 US dollars

Recordati

21,080,000 US dollars

Roche

50,000,000 US dollars

Undisclosed (calculated)

164,287,000 US dollars

Research, development and patent

427,280,000 US dollars

Selling, general and administrative

300,755,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.